US (619) 203-2886
14 Sunnyside Drive South
Owego, NY 13827
Pharmechanics was founded by Dr Sam Hoare in 2017, with the goal of helping pharmacologists analyze their data to accelerate drug discovery and basic research on drug targets. See testimonials here to see how I can support your science.
For five years I have supported Pharma and biotech clients with R&D pharmacology, enabling projects to move forward and the best drug candidates to be selected. With a wealth of experience of in vitro pharmacology in the pharmaceutical industry I can help you resolve the issues that are creating challenges in your drug discovery project.
For life science companies developing novel tools for drug discovery, I identify novel utilities and create new data analysis methodologies to increase the application and value of the products. For example, working with Montana Molecular we have developed new kinetic analysis platforms for biosensors that enable routine quantification of the kinetics of signaling for drug discovery.
For the scientific community, I develop new open-source data analysis methods that enable investigators to analyze their data in new ways, to extract extra value from new pharmacology methodologies. I run workshops and seminars to train scientists in pharmacology data analysis, including for the National Institutes of Health Assay Guidance Manual. I have published 30+ first/senior author papers on drug discovery, molecular pharmacology and data analysis.
Before founding Pharmechanics, Sam was with the Discovery Research group at Neurocrine Biosciences, where he was Lead Pharmacologist on multiple GPCR and transporter drug targets.
He is particularly known for applying receptor kinetics to small molecule drug discovery, deriving new methods for quantifying signaling kinetics, and for deciphering the mechanism of ligand interaction with Class B GPCRs.
Sam received his PhD in biochemistry from the University of Kent in 1996 and then conducted postdoctoral research at the National Institute of Mental Health.
Analyzing kinetic binding data
NIH Assay Guidance Manual, 2021
Analyzing kinetic signaling data for G-protein-coupled receptors
Scientific Reports, 2020
The importance of target binding kinetics for measuring target binding affinity in drug discovery
Drug Discovery Today, 2020
Kinetic operational models of agonism for G-protein-coupled receptors
Journal of Theoretical Biology, 2018
Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors.
Drug Discovery Today, 2005
Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.
J Pharmacol Exp Ther, 2012